Less than one in 10 individuals that would benefit from obesity jabs like Wegovy are able to get them, warns the World Health Organization as it publishes its first guidance on the medications.
Given over a billion individuals worldwide currently obese, it is advocating for more widespread and fairer availability to this class of drugs.
Based on estimates, more than two billion could be living with obesity by 2030 unless action is taken.
"The latest guidelines affirms that obesity is a chronic disease that can be managed with holistic and lifelong treatment," remarked its chief Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and supply-chain constraints are key obstacles to widespread availability to the treatments that can aid individuals in losing considerable body mass, explains the body.
GLP-1 Therapy Scarcity
Even in the present most optimistic outlook, the production of these medications would only suffice for approximately 100 million people – fewer than 10% of the global need, as stated by the health organization.
The advice urges nations and manufacturers to increase access, through strategies including voluntary licensing.
A patent on a key compound – the core ingredient of the drug Wegovy – is set to lapse in several nations in 2026.
The Way Weight-Loss Injections Operate
GLP-1 drugs imitate a biological compound to reduce digestion speed, curb appetite and increase the sense of being full so individuals eat less.
Individuals commonly begin shedding pounds in the initial weeks of beginning the regular doses.
Evidence points to users may regain a significant portion within a year of stopping the treatment, when their typical appetite come back.
To be overweight or obese elevates your likelihood for contracting diseases, including type 2 diabetes, cardiovascular issues, brain attack, and some cancers.
Obesity affects individuals in all nations and was responsible for over three and a half million fatalities worldwide in 2024, according to the WHO.
